These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30138198)

  • 21. Romiplostim.
    Cines DB; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Nov; 7(11):887-8. PubMed ID: 18974747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.
    Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T; Nakahata T
    Eur J Haematol; 2009 Apr; 82(4):247-54. PubMed ID: 19183407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romiplostin may revert the thrombocytopenia in graft-versus-host disease.
    Ruiz-Delgado GJ; Lutz-Presno J; Ruiz-Argüelles GJ
    Hematology; 2011 Mar; 16(2):108-9. PubMed ID: 21418742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 26. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia.
    Sinisalo M; Sankelo M; Itälä-Remes M
    Leuk Lymphoma; 2011 Apr; 52(4):724-5. PubMed ID: 21323511
    [No Abstract]   [Full Text] [Related]  

  • 27. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
    Kazemi T; Martin S; Worswick S
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.
    Abe M; Suzuki K; Sakata C; Sugasawa K; Hirayama F; Koga Y; Kawasaki T; Naganuma S; Itoh H
    Eur J Pharmacol; 2011 Jan; 650(1):58-63. PubMed ID: 20950606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
    Taylor N; Melchardt T; Grundbichler M; Strasser M; Egle A; Greil R
    Ann Hematol; 2013 Jul; 92(7):1001-2. PubMed ID: 23269533
    [No Abstract]   [Full Text] [Related]  

  • 33. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs.
    Qi X; De Stefano V; Guo X; Fan D
    Thromb Haemost; 2015 Jun; 113(6):1378-80. PubMed ID: 25761530
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia.
    Aslam MI; Cardile AP; Crawford GE
    J Int Assoc Provid AIDS Care; 2014; 13(1):22-3. PubMed ID: 24036490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation.
    Bosch-Vilaseca A; García-Cadenas I; Roldán E; Novelli S; Barba P; Esquirol A; Valcárcel D; Martino R; Sierra J
    Eur J Haematol; 2018 Sep; 101(3):407-414. PubMed ID: 29956377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 37. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 38. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 39. Eltrombopag in patients with chronic liver disease.
    Giannini EG; Afdhal NH
    Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.